Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology

The identification of specific genetic alterations as key oncogenic drivers and the development of targeted therapies are together transforming clinical oncology and creating a pressing need for increased breadth and throughput of clinical genotyping. Next-generation sequencing assays allow the effi...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:The Journal of molecular diagnostics : JMD Ročník 17; číslo 3; s. 251
Hlavní autori: Cheng, Donavan T, Mitchell, Talia N, Zehir, Ahmet, Shah, Ronak H, Benayed, Ryma, Syed, Aijazuddin, Chandramohan, Raghu, Liu, Zhen Yu, Won, Helen H, Scott, Sasinya N, Brannon, A Rose, O'Reilly, Catherine, Sadowska, Justyna, Casanova, Jacklyn, Yannes, Angela, Hechtman, Jaclyn F, Yao, Jinjuan, Song, Wei, Ross, Dara S, Oultache, Alifya, Dogan, Snjezana, Borsu, Laetitia, Hameed, Meera, Nafa, Khedoudja, Arcila, Maria E, Ladanyi, Marc, Berger, Michael F
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 01.05.2015
Predmet:
DNA - genetics
DNA Mutational Analysis - methods
Genotype
High-Throughput Nucleotide Sequencing - methods
Humans
Mutation
Neoplasms - genetics
Paraffin Embedding
Reproducibility of Results
ISSN:1943-7811, 1943-7811
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:The identification of specific genetic alterations as key oncogenic drivers and the development of targeted therapies are together transforming clinical oncology and creating a pressing need for increased breadth and throughput of clinical genotyping. Next-generation sequencing assays allow the efficient and unbiased detection of clinically actionable mutations. To enable precision oncology in patients with solid tumors, we developed Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT), a hybridization capture-based next-generation sequencing assay for targeted deep sequencing of all exons and selected introns of 341 key cancer genes in formalin-fixed, paraffin-embedded tumors. Barcoded libraries from patient-matched tumor and normal samples were captured, sequenced, and subjected to a custom analysis pipeline to identify somatic mutations. Sensitivity, specificity, reproducibility of MSK-IMPACT were assessed through extensive analytical validation. We tested 284 tumor samples with previously known point mutations and insertions/deletions in 47 exons of 19 cancer genes. All known variants were accurately detected, and there was high reproducibility of inter- and intrarun replicates. The detection limit for low-frequency variants was approximately 2% for hotspot mutations and 5% for nonhotspot mutations. Copy number alterations and structural rearrangements were also reliably detected. MSK-IMPACT profiles oncogenic DNA alterations in clinical solid tumor samples with high accuracy and sensitivity. Paired analysis of tumors and patient-matched normal samples enables unambiguous detection of somatic mutations to guide treatment decisions.
Bibliografia:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:1943-7811
1943-7811
DOI:10.1016/j.jmoldx.2014.12.006